Hepatitis News : New Hep C Combo Therapies Safe & Effective for Previous Non-Responders
A Smart + Strong Site
Subscribe to:
Hepatitis E-newsletter
Join Us:

Back to home » Hepatitis News » November 2012


emailprint

November 19, 2012

New Hep C Combo Therapies Safe & Effective for Previous Non-Responders

Danoprevir and mericitabine, two experimental hepatitis C virus (HCV) therapies, proved both safe and effective among patients with previous treatment experience, aidsmap reports. Jordan Feld of Toronto Western Hospital Liver Centre presented results from the MATTERHORN study at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston. For the study, he and his colleagues looked at the effects of danoprevir, a second-generation protease inhibitor, and mericitabine, a nucleoside HCV polymerase inhibitor, along with ribavirin and, in a portion of patients, pegylated interferon.

The 379-person study group included patients with HCV genotype 1 who had either responded partially or not at all to a previous round of interferon-based treatment. Partial responders received 24 weeks of therapy from one of three randomly assigned drug combinations: the interferon-free regimen of mericitabine, danoprevir and ribavirin; the mericitabine-free triple therapy of danoprevir with Pegasys (pegylated interferon alfa-2a) and ribavirin; or a quadruple therapy of mericitabine, danoprevir, ribavirin and Pegasys.  Prior null responders randomly received either the interferon-free regimen or the quad therapy for 24 weeks.

Partial and null responders taking the quad therapy experienced sustained virologic response (SVR, considered a cure) rates of 86 and 84 percent, respectively, 12 weeks after completing therapy. Partial responders taking the mericitabine-free triple therapy had a cure rate of 56 percent.

Dividing the results between genotype subcategories, researchers found that participants with genotype 1b experienced the highest cure rates, ranging between 91 and 100 percent. Meanwhile, only about three quarters of genotype 1a patients were cured on the quad therapy, and just 30 percent on the mericitabine-free triple therapy.

Other low SVR rates were among the genotype 1b patients who took the interferon-free regimen (genotype 1a patients were not assigned this combination): Partial responders had an SVR of 39 percent 12 weeks after therapy, and null responders had 55 percent.  

To read the aidsmap report, click here.

To read a study summary report, click here.

Search: hepatitis C, virus, HCV, danoprevir, mericitabine, therapy, Jordan Feld, Toronto Western Hospital Liver Centre, MATTERHORN, American Association for the Study of Liver Diseases, AASLD, polymerase inhibitor, pegylated interferon, alfa-2a, Pegasys, interferon-free, SVR, sustained virologic response, cure, genotype 1, 1a, ab, 100 percent.


Scroll down to comment on this story. Click here to visit the Hep Forums and ask questions about this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The Hep team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
Current Issue
Forums
Poll
Blogs
Hep TV
Calendar
Services Directory
Conference News
Top Stories
Treatment News
Hep Exclusives
All About Hepatitis
• Hepatitis A
Transmission
Prevention
Treatment
• Hepatitis B
Transmission
Prevention
Treatment
• Hepatitis C
Transmission
Prevention
Treatment
HCV/HIV Coinfection
Help Paying For Meds
Clinical Trials
TALK TO US
Tell us what you think
Poll
Are you a member of a hepatitis C support group?

Yes
No


Survey
Hepatitis C Reader Survey
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.